Cresco Labs (OTC: CRLBF)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Cresco Labs Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Cresco Labs Company Info
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
News & Analysis
Where Will Cresco Labs Be in 3 Years?
This cannabis company has a lot of work to do before it'll impress the market.
3 Top Cannabis Stocks to Buy for September
These are leading cannabis companies that could do well as the industry continues to grow.
Why Cresco Labs Stock Wafted Nearly 5% Higher Today
The multistate operator and its peers enjoy support at the very highest levels of the U.S. government.
Why Marijuana Stock Cresco Labs Jumped Today
Investors chose to focus on the better aspects of the company's operations following an earnings release.
This Mega Cannabis Merger Has Fallen Through: Is M&A in Cannabis Dead?
Companies have been focusing on getting leaner and more efficient, not bigger.
Are There Any Cannabis Stocks Worth Buying Right Now?
Investors remain cautious when it comes to the cannabis industry -- but could that be a mistake?
Here's How I'd Invest $10,000 Today
This portfolio would give you a mix of stability, dividends, and growth.
Cresco Labs Stock: Bear vs. Bull
Is Cresco's first-quarter performance a sign of hope or doom for this cannabis stock?
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.